Evaluation of TK1 targeting carboranyl thymidine analogs as potential delivery agents for neutron capture therapy of brain tumors

Rolf F. Barth, Weilian Yang, Robin J. Nakkula, Youngjoo Byun, Werner Tjarks, Lai Chu Wu, Peter J. Binns, Kent J. Riley

Research output: Contribution to journalArticlepeer-review

Abstract

In this report we describe studies with N5-2OH, a carboranyl thymidine analog (CTA), which is a substrate for thymidine kinase 1 (TK1), using the F98 rat glioma model. In vivo BNCT studies have demonstrated that intracerebral (i.c.) osmotic pump infusion of N5-2OH yielded survival data equivalent to those obtained with i.v. administration of boronophenylalanine (BPA). The combination of N5-2OH and BPA resulted in a modest increase in MST of F98 glioma bearing rats compared to a statistically significant increase with the RG2 glioma model, as has been previously reported by us (. Barth et al., 2008). This had lead us to synthesize a second generation of CTAs that have improved in vitro enzyme kinetics and in vivo tumor uptake ( Agarwal et al., 2015).

Original languageEnglish (US)
Pages (from-to)251-255
Number of pages5
JournalApplied Radiation and Isotopes
Volume106
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Keywords

  • BNCT
  • Carboranyl thymidine analogs
  • F98 rat glioma
  • N5-2OH

ASJC Scopus subject areas

  • Radiation

Fingerprint Dive into the research topics of 'Evaluation of TK1 targeting carboranyl thymidine analogs as potential delivery agents for neutron capture therapy of brain tumors'. Together they form a unique fingerprint.

Cite this